27 July 2018
Visiongain’ has launched a new pharma report Global Overactive Bladder Treatment Market 2018-2028: Prescription Drugs, OTC Drugs, Short-term Therapy, Long-term Therapy
It is estimated that about one in six adults in the US and Europe have over active bladder syndrome. The prevalence rate of over active bladder increases with age and thus it is expected that over active bladder will become more common in the future as the average age of people living in the developed countries is significantly increasing. The Global Overactive bladder therapeutic market is growing rapidly, with large opportunity to grow in the untapped APAC region mainly because of the introduction of low-cost generic products in rapidly developing countries such as India and China.
The lead analyst of the report commented “The global overactive bladder therapeutic market is driven by several factors such as increasing prevalence of urinary incontinence, increasing awareness of the disease and its comorbidities, growing diagnosis and treatment rates as well as limited number of current players. Moreover, there are various national and international level policies being adopted by a growing number of countries to combat overactive bladder related symptoms”
Leading companies featured in the report include Allergan, Apotex, Astellas, Medtronic, Mylan, Pfizer, Sanofi.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global Bioreactors market was estimated to be valued at US$ 9,9770.0 million in 2023 and is expected to register a CAGR of 12.2% from 2023 to 2033.
29 September 2023
The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.
27 September 2023
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
25 September 2023
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.